Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia

• Status: Completed
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the side effects of 9-Aminocamptothecin (9-AC) and to determine the best dose which should be used to treat leukemia.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Collaborators: Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Massachusetts General Hospital
• Treatments: 9-aminocamptothecin; Camptothecin

Criteria

Inclusion Criteria:

• 18 years of age or older

• AML or ALL in first or subsequent relapse, secondary AML, or CML in blastic phase

• Central venous access

• ECOG performance status of less than or equal to 2

• Bilirubin < 1.3

• SGOT < 2 x ULN

• Alkaline phosphatase < 2 x ULN

• Creatinine < 1.5

Exclusion Criteria:

• Undergone bone marrow transplantation

• Uncontrolled infection

• Other active malignancy

• HIV positivity

• Serious medical or psychiatric illness

• Pregnancy